CoChat

Duchenne muscular dystrophy: recent insights in brain related comorbidities

Vaillend, Cyrille, Aoki, Yoshitsugu, Mercuri, Eugenio, Hendriksen, Jos, Tetorou, Konstantina, Goyenvalle, Aurelie, Muntoni, Francesco · 2025 · Nature Communications
Cited by 73

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-025-56644-w

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 96

  1. Crisafulli, S. et al. Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet. J. Rare Dis. 15, 141 (2020). · DOI · Paper page
  2. Markati, T. et al. Emerging therapies for Duchenne muscular dystrophy. Lancet Neurol. 21, 814–829 (2022). · DOI
  3. Pascual-Morena, C. et al. Global prevalence of intellectual developmental disorder in dystrophinopathies: A systematic review and meta-analysis. Dev. Med Child Neurol. 65, 734–744 (2023). · DOI
  4. Darmahkasih, A. J. et al. Neurodevelopmental, behavioral, and emotional symptoms common in Duchenne muscular dystrophy. Muscle Nerve 61, 466–474 (2020). · DOI · Paper page
  5. Hendriksen, J. G. M. & Vles, J. S. H. Neuropsychiatric Disorders in Males With Duchenne Muscular Dystrophy: Frequency Rate of Attention-Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder, and Obsessive—Compulsive Disorder. 10.1177/0883073807309775 23, 477–481 (2008). · DOI · Paper page
  6. Muntoni, F., Torelli, S. & Ferlini, A. Dystrophin and mutations: One gene, several proteins, multiple phenotypes. Lancet Neurol. 2, 731–740 (2003). · DOI · Paper page
  7. Doorenweerd, N. et al. Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy. Sci. Rep. 7, 12575(2017). · DOI · Paper page
  8. Birnkrant, D. J. et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 17, 251 (2018). · DOI · Paper page
  9. García-Cruz, C. et al. Tissue-and cell-specific whole-transcriptome meta-analysis from brain and retina reveals differential expression of dystrophin complexes and new dystrophin spliced isoforms. Hum. Mol. Genet 32, 659–676 (2023). · DOI
  10. Hildyard, J. C. W. et al. Single-transcript multiplex in situ hybridisation reveals unique patterns of dystrophin isoform expression in the developing mammalian embryo. Wellcome Open Res 5, 32724863 (2020). · doi:10.12688/wellcomeopenres.15762.2
  11. Sánchez, A., Aragón, J., Ceja, V., Rendon, A. & Montanez, C. Nuclear transport and subcellular localization of the dystrophin Dp71 and Dp40 isoforms in the PC12 cell line. Biochem Biophys. Res Commun. 630, 125–132 (2022). · doi:10.1016/j.bbrc.2022.09.035
  12. Bar, S. et al. A novel product of the Duchenne muscular dystrophy gene which greatly differs from the known isoforms in its structure and tissue distribution. Biochem. J. 272, 557–560 (1990). · DOI · Paper page
  13. Tennyson, C. N., Dally, G. Y., Ray, P. N. & Worton, R. G. Expression of the dystrophin isoform Dp71 in differentiating human fetal myogenic cultures. Hum. Mol. Genet 5, 1559–1566 (1996). · doi:10.1093/hmg/5.10.1559
  14. Durbeej, M., Jung, D., Hjalt, T., Campbell, K. P. & Ekblom, P. Transient expression of Dp140, a product of the Duchenne muscular dystrophy locus, during kidney tubulogenesis. Dev. Biol. 181, 156–167 (1997). · DOI
  15. Holder -Masato Maeda, E. & Bies, R. D. Expression and regulation of the dystrophin Purkinje promoter in human skeletal muscle, heart, and brain. Hum. Genet 97, 232–239 (1996). · DOI
  16. Suzuki, Y., Higuchi, S., Aida, I., Nakajima, T. & Nakada, T. Abnormal distribution of GABAA receptors in brain of duchenne muscular dystrophy patients. Muscle Nerve 55, 591–595 (2017). · DOI
  17. Knuesel, I. et al. Short communication: altered synaptic clustering of GABAA receptors in mice lacking dystrophin (mdx mice). Eur. J. Neurosci. 11, 4457–4462 (1999). · DOI · Paper page
  18. Sekiguchi, M. et al. A deficit of brain dystrophin impairs specific amygdala GABAergic transmission and enhances defensive behaviour in mice. Brain 132, 124–135 (2009). · DOI · Paper page
  19. Pereira da Silva, J. D. et al. Altered release and uptake of gamma-aminobutyric acid in the cerebellum of dystrophin-deficient mice. Neurochem. Int. 118, 105–114 (2018). · DOI
  20. Vaillend, C. & Billard, J. M. Facilitated CA1 hippocampal synaptic plasticity in dystrophin-deficient mice: Role for GABAA receptors? Hippocampus 12, 713–717 (2002). · DOI · Paper page
  21. Wu, W. C., Bradley, S. P., Christie, J. M. & Pugh, J. R. Mechanisms and consequences of cerebellar purkinje cell disinhibition in a mouse model of duchenne muscular dystrophy. J. Neurosci. 42, 2103–2115 (2022). · DOI
  22. Kreko-Pierce, T. & Pugh, J. R. Altered synaptic transmission and excitability of cerebellar nuclear neurons in a mouse model of duchenne muscular dystrophy. Front Cell Neurosci. 16, 926518 (2022). · DOI · Paper page
  23. Zarrouki, F. et al. Abnormal expression of synaptic and extrasynaptic gabaa receptor subunits in the dystrophin-deficient mdx mouse. Int J. Mol. Sci. 23, 23 (2022). · DOI
  24. Vaillend, C. & Chaussenot, R. Relationships linking emotional, motor, cognitive and GABAergic dysfunctions in dystrophin-deficient mdx mice. Hum. Mol. Genet 26, 1041–1055 (2017).
  25. Bianchi, R. et al. Hippocampal synaptic and membrane function in the DBA/2J-mdx mouse model of Duchenne muscular dystrophy. Mol. Cell. Neurosci. 104, 103482 (2020). · DOI
  26. Araki, E. et al. Targeted Disruption of Exon 52 in the Mouse Dystrophin Gene Induced Muscle Degeneration Similar to That Observed in Duchenne Muscular Dystrophy. Biochem Biophys. Res Commun. 238, 492–497 (1997). · DOI · Paper page
  27. Hashimoto, Y. et al. Brain Dp140 alters glutamatergic transmission and social behaviour in the mdx52 mouse model of Duchenne muscular dystrophy. Prog. Neurobiol. 216, 10.1016/j.pneurobio.2022.102288 (2022). · DOI · Paper page
  28. Leyva-Leyva, M. et al. Identification of Dp140 and α1-syntrophin as novel molecular interactors of the neuronal CaV2.1 channel. Pflug. Arch. 475, 595–606 (2023). · DOI
  29. Belmaati Cherkaoui, M. et al. Dp71 contribution to the molecular scaffold anchoring aquaporine-4 channels in brain macroglial cells. Glia 69, 954–970 (2021). · DOI
  30. Lange, J. et al. Dystrophin deficiency affects human astrocyte properties and response to damage. Glia 70, 466–490 (2022). · DOI
  31. Pascual-Morena, C. et al. Dystrophin genotype and risk of neuropsychiatric disorders in dystrophinopathies: a systematic review and meta-analysis. J. Neuromuscul. Dis. 10, 159 (2023). · DOI · Paper page
  32. Weerkamp, P. M. M. et al. Wechsler scale intelligence testing in males with dystrophinopathies: a review and meta-analysis. Brain Sci 12, 10.3390/brainsci12111544 (2022). · DOI
  33. von Gontard, A. et al. Intelligence and cognitive function in children and adolescents with spinal muscular atrophy. Neuromuscul. Disord. 12, 130–136 (2002). · DOI
  34. D’alessandro, R. et al. Assessing cognitive function in neuromuscular diseases: A pilot study in a sample of children and adolescents. J. Clin. Med 10, 10 (2021). · doi:10.3390/jcm10204777
  35. Lee, I. et al. The hidden disease: delayed diagnosis in duchenne muscular dystrophy and co-occurring conditions. J. Dev. Behav. Pediatr. 43, e541–e545 (2022). · DOI
  36. Chieffo, D. P. R. et al. A longitudinal follow-up study of intellectual function in duchenne muscular dystrophy over age: is it really stable? J. Clin. Med 12, 12 (2023). · doi:10.3390/jcm12020403
  37. Norcia, G. et al. Early gross motor milestones in duchenne muscular dystrophy. J. Neuromuscul. Dis. 8, 453 (2021). · doi:10.3233/jnd-210640
  38. Chesshyre, M. et al. Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy. J. Cachexia Sarcopenia Muscle 13, 1360 (2022). · DOI · Paper page
  39. Coratti, G. et al. Longitudinal natural history in young boys with Duchenne muscular dystrophy. Neuromuscul. Disord. 29, 857–862 (2019). · doi:10.1016/j.nmd.2019.09.010
  40. Pane, M. et al. Early neurodevelopmental assessment in Duchenne muscular dystrophy. Neuromuscul. Disord. 23, 451–455 (2013). · DOI
  41. Wijekoon, N. et al. Duchenne muscular dystrophy from brain to muscle: the role of brain dystrophin isoforms in motor functions. J. Clin. Med 12, 5637 (2023). · DOI
  42. Zambon, A. A. et al. Peak functional ability and age at loss of ambulation in Duchenne muscular dystrophy. Dev. Med Child Neurol. 64, 979 (2022). · DOI
  43. Coratti, G. et al. Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy. PLoS One 17, N/A-N/A (2022). · doi:10.1371/journal.pone.0271681
  44. Pascual-Morena, C. et al. Intelligence quotient–genotype association in dystrophinopathies: A systematic review and meta-analysis. Neuropathol. Appl Neurobiol. 49, e12914 (2023). · DOI
  45. Fee, R. J., Montes, J., Stewart, J. L. & Hinton, V. J. Executive Skills and Academic Achievement in the Dystrophinopathies. J. Int. Neuropsychological Soc. 24, 928–938 (2018). · DOI · Paper page
  46. Battini, R. et al. Longitudinal data of neuropsychological profile in a cohort of Duchenne muscular dystrophy boys without cognitive impairment. Neuromuscul. Disord. 31, 319–327 (2021). · DOI
  47. Billard, C., Gillet, P., Barthez, M. A., Hommet, C. & Bertrand, P. Reading ability and processing in Duchenne muscular dystrophy and spinal muscular atrophy. Dev. Med Child Neurol. 40, 12–20 (1998). · DOI
  48. Hendriksen, J. G. M. & Vles, J. S. H. Are Males With Duchenne Muscular Dystrophy at Risk for Reading Disabilities? Pediatr. Neurol. 34, 296–300 (2006). · DOI
  49. Astrea, G. et al. Reading impairment in Duchenne muscular dystrophy: A pilot study to investigate similarities and differences with developmental dyslexia. Res Dev. Disabil. 45–46, 168–177 (2015). · DOI
  50. Schmidt-Kastner, R. Genomic approach to selective vulnerability of the hippocampus in brain ischemia-hypoxia. Neuroscience 309, 259–279 (2015). · DOI
  51. Ricotti, V. et al. Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations. Dev. Med Child Neurol. 58, 77–84 (2016). · DOI · Paper page
  52. Pane, M. et al. Attention deficit hyperactivity disorder and cognitive function in duchenne muscular dystrophy: Phenotype-genotype correlation. J. Pediatrics 161, 705–709.e1 (2012). · DOI · Paper page
  53. Pascual-Morena, C. et al. Prevalence of Neuropsychiatric Disorders in Duchenne and Becker Muscular Dystrophies: A Systematic Review and Meta-analysis. Arch. Phys. Med Rehabil. 103, 2444–2453 (2022). · DOI
  54. Trimmer, R. E., Mandy, W. P. L., Muntoni, F. & Maresh, K. E. Understanding anxiety experienced by young males with Duchenne muscular dystrophy: a qualitative focus group study. Neuromuscul. Disord. 34, 95–104 (2024). · DOI
  55. Maresh, K. et al. Startle responses in Duchenne muscular dystrophy: a novel biomarker of brain dystrophin deficiency. Brain 146, 252–265 (2023). · DOI
  56. Hendriksen, J. G. M. et al. 249th ENMC International Workshop: The role of brain dystrophin in muscular dystrophy: Implications for clinical care and translational research, Hoofddorp, The Netherlands, November 29th–December 1st 2019. Neuromuscul. Disord. 30, 782–794 (2020). · doi:10.1016/j.nmd.2020.08.357
  57. Doorenweerd, N. et al. Reduced cerebral gray matter and altered white matter in boys with Duchenne muscular dystrophy. Ann. Neurol. 76, 403–411 (2014). · DOI · Paper page
  58. Cheng, B. et al. Connectomic disturbances in Duchenne muscular dystrophy with mild cognitive impairment. Cereb. Cortex 33, 6785–6791 (2023). · DOI
  59. Biagi, L. et al. Neural substrates of neuropsychological profiles in dystrophynopathies: A pilot study of diffusion tractography imaging. PLoS One 16, 10.1371/journal.pone.0250420 (2021). · DOI · Paper page
  60. Doorenweerd, N. et al. Resting-state functional MRI shows altered default-mode network functional connectivity in Duchenne muscular dystrophy patients. Brain Imaging Behav. 15, 2297 (2021). · DOI · Paper page
  61. Preethish-Kumar, V. et al. In Vivo Evaluation of White Matter Abnormalities in Children with Duchenne Muscular Dystrophy Using DTI. https://doi.org/10.3174/ajnr.A6604. · DOI · Paper page
  62. Demirci, H. et al. Cognition of the mothers of patients with Duchenne muscular dystrophy. Muscle Nerve 62, 710–716 (2020). · DOI
  63. Wolf, T. G., Faerber, K. A., Rummel, C., Halsband, U. & Campus, G. Functional changes in brain activity using hypnosis: a systematic review. Brain Sci 12, 10.3390/brainsci12010108 (2022). · DOI
  64. Hellebrekers, D. M. J. et al. Computerized working memory training in males with Duchenne muscular dystrophy: A single case experimental design study. Neuropsychol. Rehabil. 33, 1325–1348 (2023). · DOI
  65. Cortese, S. et al. Psychopharmacology in children and adolescents: unmet needs and opportunities. Lancet Psychiatry 11, 143–154 (2024). · DOI
  66. Brusa, C. et al. Psychopharmacological treatments for mental disorders in patients with neuromuscular diseases: a scoping review. Brain Sci. 12, 10.3390/brainsci12020176 (2022). · DOI
  67. Lionarons, J. M. et al. Methylphenidate use in males with Duchenne muscular dystrophy and a comorbid attention-deficit hyperactivity disorder. Eur. J. Paediatr. Neurol. 23, 152–157 (2019). · DOI · Paper page
  68. Lee, A. J., Buckingham, E. T., Kauer, A. J. & Mathews, K. D. Descriptive phenotype of obsessive compulsive symptoms in males with Duchenne Muscular Dystrophy. J. Child Neurol. 33, 572 (2018). · DOI · Paper page
  69. Weerkamp, P. M. M. et al. Psychopharmaceutical treatment for neurobehavioral problems in Duchenne muscular dystrophy: a descriptive study using real-world data. Neuromuscul. Disord. 33, 619–626 (2023). · DOI
  70. Gadaleta, G. et al. Adults living with Duchenne muscular dystrophy: old and new challenges in a cohort of 19 patients in their third to fifth decade. Eur. J. Neurol. 31, e16060 (2024). · DOI
  71. Nart, L., Desikan, M., Pietrusz, A., Savvatis, K. & Quinlivan, R. Neurodiversity, treatment compliance and survival in adults with Duchenne muscular dystrophy: a single-centre retrospective cohort review. Neuromuscul. Disord. 35, 13–18 (2024). · DOI
  72. Bouquillon, L. et al. Workshop report: Workshop on psychiatric prescribing and psychology testing and intervention in children and adults with Duchenne muscular dystrophy. Res. Ideas Outcomes 10 10, e119243 (2024). · DOI
  73. Kamenov, K., Twomey, C., Cabello, M., Prina, A. M. & Ayuso-Mateos, J. L. The efficacy of psychotherapy, pharmacotherapy and their combination on functioning and quality of life in depression: a meta-analysis. Psychol. Med 47, 414–425 (2017). · DOI · Paper page
  74. Van Putten, M. et al. Mouse models for muscular dystrophies: an overview. https://doi.org/10.1242/dmm.043562 (2020). · DOI
  75. Bellissimo, C. A. et al. Memory impairment in the D2.mdx mouse model of Duchenne muscular dystrophy is prevented by the adiponectin receptor agonist ALY688. Exp. Physiol. 108, 1108–1117 (2023). · DOI
  76. Phillips, R. G. & LeDoux, J. E. Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav. Neurosci. 106, 274–285 (1992). · DOI · Paper page
  77. Nonneman, D. J., Brown-Brandl, T., Jones, S. A., Wiedmann, R. T. & Rohrer, G. A. A defect in dystrophin causes a novel porcine stress syndrome. BMC Genomics 13, 1–9 (2012). · DOI
  78. Caudal, D. et al. Characterization of brain dystrophins absence and impact in dystrophin-deficient Dmdmdx rat model. PLoS One 15, e0230083 (2020). · DOI · Paper page
  79. Razzoli, M. et al. Social stress is lethal in the mdx model of Duchenne muscular dystrophy. EBioMedicine 55, 102700 (2020). · DOI · Paper page
  80. Saoudi, A. et al. Emotional behavior and brain anatomy of the mdx52 mouse model of Duchenne muscular dystrophy. Dis. Model Mech. 14, dmm049028 (2021). · DOI · Paper page
  81. Verhaeg, M. et al. Learning, memory and blood–brain barrier pathology in Duchenne muscular dystrophy mice lacking Dp427, or Dp427 and Dp140. Genes Brain Behav. 23, 10.1111/gbb.12895 (2024). · DOI · Paper page
  82. Vaillend, C. et al. Spatial discrimination learning and CA1 hippocampal synaptic plasticity in mdx and mdx3cv mice lacking dystrophin gene products. Neuroscience 86, 53–66 (1998). · DOI · Paper page
  83. Vaillend, C. & Ungerer, A. Behavioral characterization of mdx3cv mice deficient in C-terminal dystrophins. Neuromuscul. Disord. 9, 296–304 (1999). · DOI · Paper page
  84. Chaussenot, R., Amar, M., Fossier, P. & Vaillend, C. Dp71-dystrophin deficiency alters prefrontal cortex excitation-inhibition balance and executive functions. Mol. Neurobiol. 56, 2670–2684 (2019). · DOI · Paper page
  85. Miranda, R. et al. Social and emotional alterations in mice lacking the short dystrophin-gene product, Dp71. Behav. Brain Funct. 20, 10.1186/s12993-024-00246-x (2024). · DOI
  86. Crawford, A. H., Hornby, N. L., de la Fuente, A. G. & Piercy, R. J. Brain magnetic resonance imaging in the DE50-MD dog model of Duchenne muscular dystrophy reveals regional reductions in cerebral gray matter. BMC Neurosci. 24, 1–9 (2023). · DOI · Paper page
  87. Crawford, A. H. et al. Validation of DE50-MD dogs as a model for the brain phenotype of Duchenne muscular dystrophy. DMM Dis. Model. Mech. 15, dmm049291 (2022). · DOI · Paper page
  88. Stirm, M. et al. A scalable, clinically severe pig model for Duchenne muscular dystrophy. DMM Dis. Model. Mech. 14, dmm049285 (2021). · DOI · Paper page
  89. Goyenvalle, A. et al. Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nat. Med. 2015 21:3 21, 270–275 (2015).
  90. Dallérac, G. et al. Rescue of a dystrophin-like protein by exon skipping normalizes synaptic plasticity in the hippocampus of the mdx mouse. Neurobiol. Dis. 43, 635–641 (2011). · DOI · Paper page
  91. Saoudi, A. et al. Partial restoration of brain dystrophin by tricyclo-DNA antisense oligonucleotides alleviates emotional deficits in mdx52 mice. Mol. Ther. Nucleic Acids 32, 173–188 (2023). · DOI
  92. Helleringer, R. et al. Cerebellar synapse properties and cerebellum-dependent motor and non-motor performance in Dp71-null mice. DMM Disease Models and Mechanisms 11, 10.1242/dmm.033258 (2018). · DOI · Paper page
  93. Miranda, R. et al. Altered social behavior and ultrasonic communication in the dystrophin-deficient mdx mouse model of Duchenne muscular dystrophy. Mol. Autism 6, 10.1186/s13229-015-0053-9 (2015). · DOI · Paper page
  94. Daoud, F. et al. Role of mental retardation-associated dystrophin-gene product dp71 in excitatory synapse organization, synaptic plasticity and behavioral functions. PLoS One 4, e6574 (2009). · DOI · Paper page
  95. Chaussenot, R. et al. Cognitive dysfunction in the dystrophin-deficient mouse model of Duchenne muscular dystrophy: A reappraisal from sensory to executive processes. Neurobiol. Learn Mem. 124, 111–122 (2015). · DOI · Paper page
  96. Michael, N. & Karen, A. Dystrophin Dp71 and the Neuropathophysiology of Duchenne Muscular Dystrophy. Mol Neurobiol. 57, 1748–1767 (2020). · DOI

Cited by

See all 73

Metadata

Authors
Vaillend, C., Aoki, Y., Mercuri, E., Hendriksen, J., Tetorou, K., Goyenvalle, A., & Muntoni, F.
Venue
Nature Communications
Published
2025-02-03
Volume
16
Issue
1
ISSN
2041-1723
Cited by
73
References
4
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Duchenne muscular dystrophy: recent insights in brain related comorbidities. https://app.cochat.ai/papers/10.1038/s41467-025-56644-w
The paper
Vaillend, C., Aoki, Y., Mercuri, E., Hendriksen, J., Tetorou, K., Goyenvalle, A., & Muntoni, F. (2025). Duchenne muscular dystrophy: recent insights in brain related comorbidities. Nature Communications. https://doi.org/10.1038/s41467-025-56644-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.